Mass or molar? Recommendations for reporting concentrations of therapeutic drugs

G.R.D. Jones, S. Bryant, R.O. Fullinfaw, Kenneth Ilett, J.O. Miners, R.G. Morris, M.P. Doogue

    Research output: Contribution to journalArticle

    5 Citations (Scopus)

    Abstract

    A working party (WP) from the Australasian Association of Clinical Biochemists, Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists, Royal College of Pathologists of Australasia and Royal Australasian College of Physicians recommends the following: • mass units should be used for reporting therapeutic drug concentrations in Australia and New Zealand; and • the litre (L) should be used as the denominator when expressing concentration. Examples of these units are mg/L and μg/L. Exceptions to these principles include: • drugs for which there is current uniformity of reporting and supporting information using molar units, notably lithium (μmol/L) and methotrexate (μmol/L); • drugs that are also present as endogenous substances, where the units used routinely should continue to be used. This applies to many substances, including minerals (eg, iron; μmol/L), vitamins (eg, vitamin D; nmol/L) and hormones (eg, thyroxine; pmol/L). • drugs for which the denominator is not a volume of fluid and there is international uniformity of reporting (eg, thiopurine metabolites; per 109 red blood cells). These recommendations relate to drugs that are used therapeutically, whether measured for therapeutic drug monitoring purposes or for assessment of overdose. Other substances, such as drugs of misuse, heavy metals or environmental toxins, were not considered by the WP and are thus not covered by this document. These recommendations should also be applied to other supporting documentation such as published guidelines, journal articles and websites. The implementation of these recommendations in New Zealand is subject to local confirmation.
    Original languageEnglish
    Pages (from-to)1-4
    JournalMedical Journal of Australia
    Volume198
    Issue number7
    DOIs
    Publication statusPublished - 2013

    Fingerprint

    Pharmaceutical Preparations
    ferrous sulfate
    New Zealand
    Therapeutics
    Australasia
    Drug Monitoring
    Heavy Metals
    Thyroxine
    Lithium
    Methotrexate
    Vitamin D
    Vitamins
    Documentation
    Minerals
    Erythrocytes
    Hormones
    Guidelines
    Physicians
    Pathologists

    Cite this

    Jones, G. R. D., Bryant, S., Fullinfaw, R. O., Ilett, K., Miners, J. O., Morris, R. G., & Doogue, M. P. (2013). Mass or molar? Recommendations for reporting concentrations of therapeutic drugs. Medical Journal of Australia, 198(7), 1-4. https://doi.org/10.5694/mja12.10366
    Jones, G.R.D. ; Bryant, S. ; Fullinfaw, R.O. ; Ilett, Kenneth ; Miners, J.O. ; Morris, R.G. ; Doogue, M.P. / Mass or molar? Recommendations for reporting concentrations of therapeutic drugs. In: Medical Journal of Australia. 2013 ; Vol. 198, No. 7. pp. 1-4.
    @article{79126bec654a4f2fac0e5cd5cf961fd2,
    title = "Mass or molar? Recommendations for reporting concentrations of therapeutic drugs",
    abstract = "A working party (WP) from the Australasian Association of Clinical Biochemists, Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists, Royal College of Pathologists of Australasia and Royal Australasian College of Physicians recommends the following: • mass units should be used for reporting therapeutic drug concentrations in Australia and New Zealand; and • the litre (L) should be used as the denominator when expressing concentration. Examples of these units are mg/L and μg/L. Exceptions to these principles include: • drugs for which there is current uniformity of reporting and supporting information using molar units, notably lithium (μmol/L) and methotrexate (μmol/L); • drugs that are also present as endogenous substances, where the units used routinely should continue to be used. This applies to many substances, including minerals (eg, iron; μmol/L), vitamins (eg, vitamin D; nmol/L) and hormones (eg, thyroxine; pmol/L). • drugs for which the denominator is not a volume of fluid and there is international uniformity of reporting (eg, thiopurine metabolites; per 109 red blood cells). These recommendations relate to drugs that are used therapeutically, whether measured for therapeutic drug monitoring purposes or for assessment of overdose. Other substances, such as drugs of misuse, heavy metals or environmental toxins, were not considered by the WP and are thus not covered by this document. These recommendations should also be applied to other supporting documentation such as published guidelines, journal articles and websites. The implementation of these recommendations in New Zealand is subject to local confirmation.",
    author = "G.R.D. Jones and S. Bryant and R.O. Fullinfaw and Kenneth Ilett and J.O. Miners and R.G. Morris and M.P. Doogue",
    year = "2013",
    doi = "10.5694/mja12.10366",
    language = "English",
    volume = "198",
    pages = "1--4",
    journal = "Medical Journal Australia",
    issn = "0025-729X",
    publisher = "Australasian Medical Publishing Co. Ltd",
    number = "7",

    }

    Jones, GRD, Bryant, S, Fullinfaw, RO, Ilett, K, Miners, JO, Morris, RG & Doogue, MP 2013, 'Mass or molar? Recommendations for reporting concentrations of therapeutic drugs' Medical Journal of Australia, vol. 198, no. 7, pp. 1-4. https://doi.org/10.5694/mja12.10366

    Mass or molar? Recommendations for reporting concentrations of therapeutic drugs. / Jones, G.R.D.; Bryant, S.; Fullinfaw, R.O.; Ilett, Kenneth; Miners, J.O.; Morris, R.G.; Doogue, M.P.

    In: Medical Journal of Australia, Vol. 198, No. 7, 2013, p. 1-4.

    Research output: Contribution to journalArticle

    TY - JOUR

    T1 - Mass or molar? Recommendations for reporting concentrations of therapeutic drugs

    AU - Jones, G.R.D.

    AU - Bryant, S.

    AU - Fullinfaw, R.O.

    AU - Ilett, Kenneth

    AU - Miners, J.O.

    AU - Morris, R.G.

    AU - Doogue, M.P.

    PY - 2013

    Y1 - 2013

    N2 - A working party (WP) from the Australasian Association of Clinical Biochemists, Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists, Royal College of Pathologists of Australasia and Royal Australasian College of Physicians recommends the following: • mass units should be used for reporting therapeutic drug concentrations in Australia and New Zealand; and • the litre (L) should be used as the denominator when expressing concentration. Examples of these units are mg/L and μg/L. Exceptions to these principles include: • drugs for which there is current uniformity of reporting and supporting information using molar units, notably lithium (μmol/L) and methotrexate (μmol/L); • drugs that are also present as endogenous substances, where the units used routinely should continue to be used. This applies to many substances, including minerals (eg, iron; μmol/L), vitamins (eg, vitamin D; nmol/L) and hormones (eg, thyroxine; pmol/L). • drugs for which the denominator is not a volume of fluid and there is international uniformity of reporting (eg, thiopurine metabolites; per 109 red blood cells). These recommendations relate to drugs that are used therapeutically, whether measured for therapeutic drug monitoring purposes or for assessment of overdose. Other substances, such as drugs of misuse, heavy metals or environmental toxins, were not considered by the WP and are thus not covered by this document. These recommendations should also be applied to other supporting documentation such as published guidelines, journal articles and websites. The implementation of these recommendations in New Zealand is subject to local confirmation.

    AB - A working party (WP) from the Australasian Association of Clinical Biochemists, Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists, Royal College of Pathologists of Australasia and Royal Australasian College of Physicians recommends the following: • mass units should be used for reporting therapeutic drug concentrations in Australia and New Zealand; and • the litre (L) should be used as the denominator when expressing concentration. Examples of these units are mg/L and μg/L. Exceptions to these principles include: • drugs for which there is current uniformity of reporting and supporting information using molar units, notably lithium (μmol/L) and methotrexate (μmol/L); • drugs that are also present as endogenous substances, where the units used routinely should continue to be used. This applies to many substances, including minerals (eg, iron; μmol/L), vitamins (eg, vitamin D; nmol/L) and hormones (eg, thyroxine; pmol/L). • drugs for which the denominator is not a volume of fluid and there is international uniformity of reporting (eg, thiopurine metabolites; per 109 red blood cells). These recommendations relate to drugs that are used therapeutically, whether measured for therapeutic drug monitoring purposes or for assessment of overdose. Other substances, such as drugs of misuse, heavy metals or environmental toxins, were not considered by the WP and are thus not covered by this document. These recommendations should also be applied to other supporting documentation such as published guidelines, journal articles and websites. The implementation of these recommendations in New Zealand is subject to local confirmation.

    U2 - 10.5694/mja12.10366

    DO - 10.5694/mja12.10366

    M3 - Article

    VL - 198

    SP - 1

    EP - 4

    JO - Medical Journal Australia

    JF - Medical Journal Australia

    SN - 0025-729X

    IS - 7

    ER -